Subscribe to Search results

A survey published in the "British Medical Journal" showed that a fifth of centres were using heat treated commercial Factor 9.

Published on:

The CBLA agreed to finance the trial of 8CRV.

Published on:

PFC routinely issued heat-treated Factor 9 from August 1985.

Published on:

Dr Foster stated that observations confirmed that Factor 8 activity could be destroyed even by modest increases in temperature, and at the time it seemed inconceivable that Factor 8 could be heat treated at a temperature high enough to eliminate the risk of hepatitis transition.

Published on:

Scotland produced DEFIX and similarly to BPL/PFL's 9A product, there were worries It could lead to thrombosis in some cases.

Published on:

PFC Liberton first issued Factor 8 from plasma tested for HIV/HTLV-3 antibody in February 1986.

Published on:

Dr Joel Spero stated that a major effort was necessary to develop a 'clean' product rapidly, in order to treat the next generation of haemophilia patients.

Published on:

Dr Foster reported to the directors of SNBTS at their meeting that the Factor 8 concentrate being issued were derived from unscreened plasma, but it was anticipated the position would change soon.

Published on:

Immuno, Vienna concentrated on a virucidal process to inactivate hepatitis viruses. This was announced to many of the UKHCDO Directors and Dr Craske at a meeting, and it was said the early results had been successful.

Published on:

Dr Perry wrote to five Scottish regions and Belfast to tell them on 10 or 11 December they would be supplied with sufficient heat-treated product to cover a month and continuous supply would be made thereafter in sufficient quantities to enable non-heat-treated product to be recalled.

Published on:

Scotland was ahead of England and had started to heat Factor 8 stocks in a way which would inactivate HTLV-3 from 18 November 1984.

Published on:

Although a universal Hepatitis B vaccine only began in the UK in 2017, a few children with haemophilia were vaccinated in the early 1980s.

Published on:

It was reported that there was a higher risk of hepatitis from commercially obtained blood than from blood from unpaid donors.

Published on:

Alpha had a 22% level of hepatitis infection from commercial products at the start of 1986.

Published on:

In February 1986 the possibility that Factorate HT, Armour's heat-treated Factor 8 product, might have caused HIV transmission became widespread knowledge.

Published on:

Alter et al in the article "The Ausria Test: Critical Evaluation of Sensitivity and Specificity" concluded that "the single most significant measure for the reduction of posttransfusion hepatitis is the total exclusion of the commercial donor."

Published on:

The original CDC experiments on heat treatment had been conducted with Cutter's and Alpha's products and then Hyland asked CDC to conduct similar tests on their product, with similar results.

Published on:

The enormous differences between the safety of blood from volunteers and that commercially obtained "have been repeatedly pointed out by this laboratory during the past decade".

Published on:

It was reported that commercially obtained blood was not as safe as volunteer obtained blood.

Published on:

The order of priority for Factor 8 products was: Factor 7Y [from] BPL, Haemate P [from] Behring, Profilate [from] Alpha.

Published on: